SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Kemble George (Last) (First) (Middle) SAGIMET BIOSCIENCES INC. 155 BOVET RD., SUITE 303 (Street) SAN MATEO CA 94402 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Sagimet Biosciences Inc. [ SGMT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/18/2023
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.79	07/18/2023		D(1)			5,630	(2)	09/26/2023	Common Stock	5,630	$0	0	D
Stock Option (Right to Buy)	$0.79	07/18/2023		A(1)		5,630		(2)	09/26/2023	Series A Common Stock	5,630	$0	5,630	D
Stock Option (Right to Buy)	$11.13	07/18/2023		D(1)			3,179	(2)	03/12/2024	Common Stock	3,179	$0	0	D
Stock Option (Right to Buy)	$11.13	07/18/2023		A(1)		3,179		(2)	03/12/2024	Series A Common Stock	3,179	$0	3,179	D
Stock Option (Right to Buy)	$23.05	07/18/2023		D(1)			7,147	(2)	12/16/2024	Common Stock	7,147	$0	0	D
Stock Option (Right to Buy)	$23.05	07/18/2023		A(1)		7,147		(2)	12/16/2024	Series A Common Stock	7,147	$0	7,147	D
Stock Option (Right to Buy)	$19.87	07/18/2023		D(1)			26,352	(2)	10/12/2025	Common Stock	26,352	$0	0	D
Stock Option (Right to Buy)	$19.87	07/18/2023		A(1)		26,352		(2)	10/12/2025	Series A Common Stock	26,352	$0	26,352	D
Stock Option (Right to Buy)	$6.36	07/18/2023		D(1)			367,824	(2)	04/27/2029	Common Stock	367,824	$0	0	D
Stock Option (Right to Buy)	$6.36	07/18/2023		A(1)		367,824		(2)	04/27/2029	Series A Common Stock	367,824	$0	367,824	D
Stock Option (Right to Buy)	$6.36	07/18/2023		D(1)			46,432	(2)	04/27/2029	Common Stock	46,432	$0	0	D
Stock Option (Right to Buy)	$6.36	07/18/2023		A(1)		46,432		(2)	04/27/2029	Series A Common Stock	46,432	$0	46,432	D
Stock Option (Right to Buy)	$6.36	07/18/2023		D(1)			526,332	(3)	01/26/2031	Common Stock	526,332	$0	0	D
Stock Option (Right to Buy)	$6.36	07/18/2023		A(1)		526,332		(3)	01/26/2031	Series A Common Stock	526,332	$0	526,332	D
Stock Option (Right to Buy)	$7.15	07/18/2023		D(1)			21,173	(4)	10/16/2032	Common Stock	21,173	$0	0	D
Stock Option (Right to Buy)	$7.15	07/18/2023		A(1)		21,173		(4)	10/16/2032	Series A Common Stock	21,173	$0	21,173	D

Explanation of Responses:

1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

2. This option is fully vested and exercisable as of the date hereof.

3. The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.

4. 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Dennis Hom, Attorney-in-Fact	07/20/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.